Denali Therapeutics Files 8-K
Ticker: DNLI · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-update
TL;DR
Denali Therapeutics filed an 8-K on Jan 7 for a Jan 6 event - likely regulatory/financial updates.
AI Summary
Denali Therapeutics Inc. filed an 8-K on January 7, 2025, reporting an event on January 6, 2025. The filing is related to Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located at 161 Oyster Point Blvd., South San Francisco, CA 94080.
Why It Matters
This 8-K filing indicates a regulatory disclosure and potential financial updates from Denali Therapeutics, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for regulatory and exhibit purposes and does not appear to contain immediate material adverse information.
Key Numbers
- 001-38311 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-3872213 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
- January 7, 2025 (date) — Date of Report
- 161 Oyster Point Blvd. (location) — Principal executive offices address
- South San Francisco, California (location) — Principal executive offices city and state
FAQ
What specific event occurred on January 6, 2025, that necessitated this 8-K filing?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as the items of disclosure, suggesting a material event or update was communicated or is being filed.
What is the primary business of Denali Therapeutics Inc. according to the filing?
The filing categorizes Denali Therapeutics Inc. under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Where are Denali Therapeutics Inc.'s principal executive offices located?
The principal executive offices are located at 161 Oyster Point Blvd., South San Francisco, California 94080.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SEC file number for Denali Therapeutics Inc.?
The SEC file number for Denali Therapeutics Inc. is 001-38311.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-06 18:13:37
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI NASDAQ Global Select Mar
Filing Documents
- dnli-20250106.htm (8-K) — 31KB
- exhibit991pressrelease10625.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 13KB
- 0001714899-25-000007.txt ( ) — 193KB
- dnli-20250106.xsd (EX-101.SCH) — 2KB
- dnli-20250106_lab.xml (EX-101.LAB) — 21KB
- dnli-20250106_pre.xml (EX-101.PRE) — 12KB
- dnli-20250106_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 6, 2025, Denali Therapeutics Inc. (the "Company") issued a press release announcing topline results for Regimen G evaluating eIF2B agonist DNL343 in the Phase 2/3 HEALEY ALS platform trial. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 6, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: January 7, 2025 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer